Affimed N.V.
AFMD · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.05 | -0.07 | 3.33 | 6.05 |
| FCF Yield | -134.95% | -64.05% | -15.59% | -4.99% |
| EV / EBITDA | -0.64 | 0.09 | -6.27 | -7.36 |
| Quality | ||||
| ROIC | -137.41% | -51.18% | -39.56% | -31.77% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 1.04 | 1.22 | 1.51 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | -41.04% | 13.40% | 23.57% | 6.11% |
| Free Cash Flow Growth | -7.96% | -16.75% | -355.85% | 35.01% |
| Safety | ||||
| Net Debt / EBITDA | 0.19 | 2.11 | 2.80 | 4.25 |
| Interest Coverage | -59.06 | -54.06 | -89.93 | -365.45 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 234.97 | 23.80 | 43.48 | 31.39 |